+

Issue of Share Options

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of 0.2p each in the Company (“Share Options”) on 30 June 2020, to certain members of the Company’s senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the IPO and are governed by the rules of the Company’s Employee Share Option Plan (“ESOP”).

Share Options were granted as follows:

Name Number of Share Options granted Total no. of ordinary shares under option post grant % of existing issued share capital
Damian Thornton (COO and PDMR) 4,200 102,704 0.12%
Jordan Clark (CTO and PDMR) 4,200 76,114 0.09%
Susanne Munksted (CPO and PDMR) 4,200 70,672 0.08%

A further 214,500 Share Options were granted to 51 employees, each of whom received 4,200 Share Options.

The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 0.2p per share being the nominal value of the share.

Following the grant the total number of share options outstanding granted to the Company’s Directors, senior management team and key employees is 1,790,762, representing approximately 2.13% of the Company’s current issued share capital of 84,068,923.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Damian Thornton
2 Reason for notification
a. Position/Status Chief Operating Officer
b. Initial notification/

Amendment

Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN: GB00BJQTGV64

b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 4,200
e. Date of the transaction 30 June 2020
f. Place of the transaction Outside a trading venue

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Jordan Clark
2 Reason for notification
a. Position/Status Chief Technology Officer
b. Initial notification/

Amendment

Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN: GB00BJQTGV64

b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 4,200
e. Date of the transaction 30 June 2020
f. Place of the transaction Outside a trading venue

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Susanne Munksted
2 Reason for notification
a. Position/Status Chief Precision Officer
b. Initial notification/

Amendment

Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN: GB00BJQTGV64

b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 4,200
e. Date of the transaction 30 June 2020
f. Place of the transaction Outside a trading venue

Enquiries:

Diaceutics PLC www.diaceutics.com
Stuart Hunt, Head of Investor Relations +44 (0) 7815 778 536
Cenkos Securities plc (Nominated adviser and broker) +44 (0) 20 7391 8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893

About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Diagnostic Network solution for the development and commercialization of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com

Latest Blogs

Latest Blogs